Bluebird Bio's "Impressive" Killer T-Cells Battle Myeloma, But Are Not A Cure Yet

A treatment that genetically modifies a patient's own white blood cells to attack the cancer multiple myeloma had "impressive" results in an early clinical trial, experts say. But it is not a cure, and could still face tough competition from other therapies.